Why Cirrhosis Patients Have Regular Ultrasound Scans and Blood Tests: Surveillance Explained

Key Takeaways
- Hepatocellular carcinoma develops mostly in livers that are already cirrhotic, because decades of cell death and regrowth accumulate genetic errors in regenerating nodules.
- The NHS offers people with cirrhosis an ultrasound and blood tests about every six months, an interval chosen to catch slow-growing tumors while they are still small.
- A normal AFP does not rule out liver cancer, since many early tumors never produce the marker, and a raised AFP can occur without any cancer at all.
- An enlarged spleen on the scan and a falling platelet count in the bloods are two faces of the same problem: rising pressure in the portal vein.
- Ultrasound can strongly suggest cirrhosis through a nodular surface and coarse texture, but diagnosis usually combines blood tests, elastography and sometimes biopsy.
- Fatty liver and abdominal fat scatter sound waves, so people with metabolic cirrhosis more often need CT or MRI when the ultrasound visualization score is poor.
People with cirrhosis have an ultrasound scan and blood tests about every six months because scarred liver tissue carries a higher risk of liver cancer, and small tumors cause no symptoms. The scan looks for new nodules, spleen enlargement and fluid; the blood tests track how well the liver is working and may include the AFP tumor marker. Regular checks let the care team act early.
The gel is always colder than he expects. Twice a year, the same darkened room, the same sweep of the probe under his ribs while the sonographer asks him to hold his breath. He feels well. He walks the dog, works a full week, and stopped drinking years ago. So why, he asks the nurse every time, does cirrhosis ultrasound surveillance keep bringing him back here, along with a vial of blood drawn in the corridor outside?
That question sits at the heart of living with a scarred liver. Cirrhosis itself can be surprisingly quiet. The risk it carries is not. Regular scanning and blood work are the way a care team watches for two things that rarely announce themselves until late: a small liver tumor, and the slow pressure changes that lead to bleeding, fluid and confusion.
This explainer walks through what the scan actually shows, what each blood test means, who is offered this program, and what happens when something turns up.
What is cirrhosis ultrasound surveillance, and why every six months?
Cirrhosis is the late stage of liver scarring, in which bands of fibrous tissue replace working liver cells and distort the organ’s structure. Surveillance means looking for a disease, at regular intervals, in people already known to be at higher risk of it, before any symptoms appear. In cirrhosis, the disease being looked for is hepatocellular carcinoma (HCC), the cancer that grows from liver cells themselves and the most common form of primary liver cancer.
The program usually pairs an abdominal ultrasound with a set of blood tests, and the standard rhythm is roughly every six months. The NHS describes exactly this offer for people with cirrhosis: scans and blood tests at six-month intervals to check for liver cancer. The interval is not arbitrary. Small liver tumors tend to grow slowly enough that a six-month gap gives a reasonable chance of catching one while it is still small, yet not so often that the appointments themselves become a burden with little added benefit.
The most useful way to think about it is as two parallel conversations. The ultrasound asks a structural question: has anything new appeared inside the liver, and how is the plumbing around it coping? The blood tests ask a functional question: how much work is this scarred organ still able to do, and is that changing? Neither answers the other’s question well on its own, which is why they travel together.
What surveillance is not: it is not a test that proves the liver is healthy, and a clear scan does not mean the scarring has reversed. It is a way of buying time, so that if a problem develops, the care team sees it while the widest range of options is still open.
Why does a scarred liver raise the risk of liver cancer?
A liver has a remarkable ability to regrow. In cirrhosis that strength becomes a liability. Whatever is injuring the organ, whether alcohol, a virus, fat-related inflammation or an immune attack, kills liver cells year after year, and the survivors divide to replace them. Every round of division is another chance for a copying error in a cell’s DNA. Over decades, the scar bands and the islands of regenerating cells between them, called regenerative nodules, create a landscape in which some nodules pick up enough genetic damage to become dysplastic (abnormal but not yet cancer) and, in a minority, frankly cancerous.

This is why most hepatocellular carcinoma arises in livers that are already cirrhotic, a point made plainly in Mayo Clinic’s overview of liver cancer, which lists cirrhosis as a leading risk factor. The scarring and the cancer share the same root cause: chronic injury.
Some causes add their own risk on top. Hepatitis B virus can insert its genetic material directly into liver cells, so people with chronic hepatitis B can develop HCC even before cirrhosis has formed, which is why the CDC describes liver cancer as a potential long-term complication of chronic infection. Iron overload from hemochromatosis and the combination of cirrhosis with diabetes or obesity also tend to nudge risk upward.
The practical consequence is simple and a little uncomfortable. Early HCC produces no pain, no weight loss, no jaundice. By the time a liver tumor causes symptoms, it is usually large or has spread within the liver. Feeling well is therefore not reassurance in itself; it is the normal state of someone whose tumor, if present, is still small enough to treat. That gap between no symptoms and late symptoms is the window surveillance is designed to fill.
How does a cirrhosis ultrasound surveillance scan actually work?
Ultrasound uses high-frequency sound waves, far above the range of hearing, sent into the body from a handheld probe called a transducer. Different tissues bounce the sound back at different strengths and speeds, and a computer turns those echoes into a moving grayscale image. No radiation is involved and no injection is needed for a standard surveillance scan.
You will usually be asked not to eat for a few hours beforehand, because a full stomach and gas-filled bowel sit in front of the liver and block the view. In the room, you lie on your back and then on your left side, the gel goes on, and the sonographer works systematically through the liver, segment by segment, often asking you to take a deep breath and hold it so the liver drops below the rib cage.
Three things are being hunted. First, any nodule that was not there before, or any existing nodule that has grown. The sonographer measures each one and notes its appearance. Second, the state of the blood vessels: a Doppler setting, which shows the direction and speed of blood flow in color, checks that blood in the portal vein (the large vein carrying blood from the gut to the liver) is flowing toward the liver and that no clot has formed. Third, the surroundings: spleen size, free fluid in the abdomen, and the texture of the liver surface.
Many departments report the scan using US LI-RADS, a standardized system that grades the result as negative, subthreshold (a tiny nodule below the size that warrants further imaging) or positive, and separately scores how well the liver could be seen. That second score matters more than people realize, because a scan that is technically clear but poorly visualized is not the same as a reassuring one.
Can ultrasound detect cirrhosis, or only suggest it?
People often ask whether cirrhosis can be diagnosed by ultrasound alone. The honest answer is that ultrasound can strongly suggest cirrhosis, but it rarely settles the question by itself.

An established cirrhotic liver has a recognizable look. The surface, normally smooth, becomes bumpy or nodular. The internal texture turns coarse and uneven. The right lobe often shrinks while the caudate lobe, a small segment near the back, enlarges in compensation. Around the liver, the sonographer may see an enlarged spleen, free fluid, widened veins or reversed flow in the portal vein. When several of these appear together in someone with a known cause of liver injury, the picture is fairly convincing.
The problem is early cirrhosis. A liver can be significantly scarred and still look close to normal on a standard scan, and some of the signs overlap with other conditions. That is why diagnosis normally rests on a combination. The NHS describes blood tests, imaging, and increasingly transient elastography, a specialized scan that measures how stiff the liver is by sending a gentle shear wave through it; stiffer tissue means more scarring. Where results conflict or the cause is unclear, a liver biopsy, in which a thin needle removes a sliver of tissue for the microscope, may still be used.
For someone already in a surveillance program, this distinction has a practical edge. The scan is not being repeated every six months to re-prove the diagnosis. Its job has shifted from asking whether the liver is scarred to asking whether anything new has grown within the scar. Reading the report with that purpose in mind makes the language less alarming; a note of coarse echotexture is simply the known background, not a fresh finding.
Cirrhosis blood tests explained: what each number tells your team
The blood draw that accompanies the scan is not one test but a panel, and each line answers a different question. Mayo Clinic notes that these results feed into scoring systems such as Child-Pugh and MELD, which combine several values into a single estimate of how advanced the liver disease is and are used in transplant assessment.
| Test | What it measures | Why it matters in cirrhosis |
|---|---|---|
| ALT and AST | Enzymes released from injured liver cells | Signal ongoing inflammation; can be near normal in burnt-out scarring |
| Bilirubin | Yellow pigment the liver should clear | Rising levels suggest the liver is falling behind; causes jaundice |
| Albumin | A protein the liver manufactures | Low albumin reflects reduced production capacity and promotes fluid buildup |
| INR / prothrombin time | How quickly blood clots | Clotting factors are made in the liver; prolonged times mean less reserve |
| Platelet count | Cells that help blood clot | Low counts often reflect an enlarged spleen trapping platelets |
| Creatinine and sodium | Kidney function and salt balance | Both worsen in advanced disease and are part of MELD scoring |
| AFP | Alpha-fetoprotein, a tumor marker | Raised by some liver cancers, but not all, and by other conditions |
Two patterns are worth understanding. Enzymes such as ALT measure damage happening now, so they can be deceptively calm in a liver that has already scarred and has few cells left to injure. Albumin, bilirubin and INR measure function, and it is the slow drift in these three that tells a hepatologist whether someone is moving from compensated toward decompensated disease. A single result rarely changes anything; the trend across visits does.
What does the AFP blood test add to the ultrasound?
Alpha-fetoprotein (AFP) is a protein made in large amounts by the liver of a developing fetus and in only tiny amounts by healthy adults. Some hepatocellular carcinomas switch that production back on, which is why MedlinePlus describes the AFP test as a tumor marker used in people at risk of liver cancer and in monitoring known tumors.
The key word is some. A meaningful share of early liver cancers never raise AFP, so a normal result cannot rule a tumor out. In the other direction, AFP can climb during a hepatitis flare, in active cirrhosis without any cancer, in pregnancy and with certain tumors of the testicles or ovaries. A single raised value is therefore a reason to look harder, not a diagnosis.
Because of this imperfect behavior, guidelines around the world differ on whether AFP should be part of routine surveillance at all. Some recommend ultrasound alone; others, including the NHS program, pair the scan with the blood test on the reasoning that two imperfect tools catch more between them than either does separately, and that a rising trend in AFP over several visits is more telling than any one number.
What this means at the appointment is modest. A stable, low AFP alongside a clear scan is reassuring. A steadily rising AFP with a clear scan may prompt a CT or MRI even though nothing was visible on ultrasound, because the marker can move before a tumor is large enough to see. A raised AFP with a new nodule sharpens the suspicion and speeds up the next step. In every case the interpretation belongs to the hepatology team, who read the value against the person’s history, their type of cirrhosis and their previous results.
Who is usually offered liver cancer screening in cirrhosis, and who is asked to wait?
The straightforward group is anyone with a confirmed diagnosis of cirrhosis, whatever the cause, who is well enough that a liver tumor, if found, could be treated. Guideline bodies broadly agree on this, and it covers the large majority of people in surveillance programs.
A second group qualifies without cirrhosis. People with chronic hepatitis B infection may be offered surveillance based on age, family history of liver cancer, region of origin or evidence of active liver inflammation, because the virus itself raises risk, as the CDC’s material on long-term complications of hepatitis B explains. Some centers also continue surveillance in people with advanced scarring from hepatitis C after the virus has been cleared, since existing fibrosis does not vanish when the infection does.
Who is asked to wait, or not offered the program at all? The logic is uncomfortable but consistent: surveillance only helps if finding a tumor would change what happens next. Someone whose liver failure is so advanced that they could not tolerate any tumor treatment, and who is not being considered for transplant, gains little from a scan that could only deliver bad news. Likewise, a person with serious illness elsewhere that limits life expectancy may be advised, after a frank discussion, that six-monthly imaging is unlikely to benefit them.
People with earlier-stage fibrosis, before cirrhosis has formed, are generally not enrolled, with the hepatitis B exception above. Their path is to treat the underlying cause and to be reassessed as the liver is monitored over time.
None of these boundaries are hard lines. Fitness changes, transplant status changes, and new causes of liver injury appear. The decision to start, pause or continue surveillance always rests with the treating team, revisited as circumstances shift.
Cirrhosis and enlarged spleen: why the scan looks beyond the liver
Can a cirrhotic liver cause an enlarged spleen? Yes, and the mechanism explains why the sonographer spends time on the left side of your abdomen during a liver scan.
Blood from the intestines, stomach and spleen drains into the portal vein and flows through the liver before returning to the heart. A scarred, stiff liver resists that flow. Pressure builds up behind it, a state called portal hypertension, which the NHS lists among the main complications of cirrhosis. The spleen sits at the upstream end of this traffic jam. Congested with blood, it swells, a finding called splenomegaly, and an enlarged spleen is often one of the clearest ultrasound clues that portal pressure is high.
The enlarged spleen then does something that shows up in the blood tests. It filters and holds onto more platelets than normal, so the platelet count drops. A falling platelet count in someone with cirrhosis is therefore less about a bleeding disorder and more a quiet indicator of worsening pressure, which is why the laboratory result and the scan measurement are read side by side.
High portal pressure has two other consequences the scan watches for. Blood seeking an alternative route home opens up small veins in the lining of the esophagus and stomach; stretched into varices, these can bleed heavily. Ultrasound cannot see varices directly, but an enlarged spleen, low platelets and a widened portal vein together raise suspicion and often lead to an endoscopy, in which a thin camera inspects the esophagus from the inside. The second consequence is ascites, fluid leaking into the abdominal cavity, which ultrasound detects easily and early.
So the spleen measurement in your report is not a digression. It is one of the best indirect gauges of the pressure problem that drives most of the serious, non-cancer complications of cirrhosis.
What are the different types of liver cirrhosis, and does the type change surveillance?
Cirrhosis is classified in three overlapping ways, and each tells the care team something different.
The first is by cause. Mayo Clinic lists the main ones: long-term heavy alcohol use; chronic hepatitis B or C infection; metabolic dysfunction-associated steatotic liver disease, the fat-related liver injury linked to obesity and diabetes that was previously called non-alcoholic fatty liver disease; autoimmune hepatitis, in which the immune system attacks liver cells; the bile duct diseases primary biliary cholangitis and primary sclerosing cholangitis; and inherited conditions such as hemochromatosis (iron overload) and Wilson disease (copper overload). Some people have more than one cause at once.
The second is by stage. The NHS distinguishes compensated cirrhosis, where the liver is scarred but still manages its essential work and symptoms are few, from decompensated cirrhosis, where complications such as jaundice, ascites, variceal bleeding or confusion have appeared. This is the distinction that most shapes day-to-day care.
The third, older classification is by the size of the regenerative nodules seen under the microscope, micronodular or macronodular, and it matters less in modern practice.
Does the type change the surveillance plan? Mostly in the details rather than the principle. Hepatitis B and hemochromatosis sit toward the higher end of cancer risk, so teams tend to be particularly firm about not missing appointments. Fat-related cirrhosis brings a practical problem: a fatty, often large body habitus scatters ultrasound waves and makes the liver harder to see, so these scans more often come back with a poor visualization score and a recommendation for CT or MRI instead. Autoimmune and bile duct diseases add their own monitoring, such as bile duct imaging in primary sclerosing cholangitis. The six-month ultrasound and blood tests remain the common backbone across all of them.
What happens in the days and weeks after a surveillance scan?
Most of the time, nothing dramatic. The sonographer’s images go to a radiologist for reporting, the blood results return to the hepatology clinic, and you hear back through a letter, a portal message or your next appointment. A negative scan with stable bloods simply resets the clock for another six months.
If the report describes a nodule, the next step depends on its size and the reporting category. Very small nodules, below the threshold at which further imaging is recommended, are usually handled by bringing the next ultrasound forward rather than waiting the full interval, because many such nodules are regenerative tissue and simply need to be watched. A nodule above the threshold, or any clearly suspicious feature, triggers a multiphase contrast scan: a CT or MRI in which a contrast agent is injected into a vein and images are taken at timed intervals as it passes through the liver.
That timing is the diagnostic trick. Hepatocellular carcinoma draws its blood supply from the hepatic artery rather than the portal vein, so it lights up early in the arterial phase and then washes out while the surrounding liver is still enhancing. In a cirrhotic liver, a nodule showing that characteristic pattern can be diagnosed on imaging alone, without a biopsy, which is why guidelines treat the contrast scan rather than the ultrasound as the point of diagnosis.
Blood results have their own follow-ups. A falling platelet count or rising bilirubin may prompt an endoscopy to look for varices, a review of medicines, or a conversation about whether transplant assessment should begin. A rising AFP with a clear ultrasound usually earns a contrast scan too.
Through all of this, the waiting is often the hardest part. Asking the clinic how and when results will be shared, before you leave the appointment, removes a surprising amount of that strain.
What are the limits of ultrasound, and when do CT or MRI step in?
Ultrasound is the first-line surveillance tool for sound reasons: it involves no radiation, needs no contrast injection, is widely available and can be repeated indefinitely. Its weaknesses deserve equal honesty, because they explain why some people are moved to other scans.
The central limitation is that sound waves have to travel through whatever lies between the probe and the liver. Abdominal fat scatters them. A fatty liver scatters them further and brightens the background so that a small, similarly bright nodule hides in plain sight. A severely nodular, shrunken liver is itself a lumpy landscape in which a new lump is hard to distinguish from old ones. Bowel gas and a large volume of ascites block the view. Studies pooled in systematic reviews have consistently found that ultrasound misses a meaningful fraction of early-stage tumors, with the miss rate highest in exactly the situations above. The visualization score in US LI-RADS exists to flag this: a scan graded as severely limited is a prompt to consider another method, not a clean bill of health.
Multiphase CT and MRI see through these barriers and detect smaller lesions, but they carry trade-offs. CT uses ionizing radiation, which accumulates over years of repeated scanning. Both require intravenous contrast, which needs reasonable kidney function and carries a small risk of reaction. MRI takes longer, is harder to tolerate for people who are claustrophobic, and is less available in many services. Both also find incidental shadows that lead to further tests and anxiety without changing outcomes.
Shortened MRI protocols designed specifically for surveillance are under active study and look promising, but they have not yet replaced ultrasound in major guidelines. Where someone falls on this spectrum, ultrasound alone, ultrasound plus AFP, or cross-sectional imaging, is a judgment the hepatology and radiology teams make together, based on how well that particular liver can be seen.
What is the best treatment for liver cirrhosis, and how does surveillance fit in?
People searching for the single best treatment for cirrhosis are usually hoping for one intervention that undoes the scarring. There is no such treatment, and understanding why reframes what surveillance is for.
Care rests on three pillars, which the NHS summarizes in its treatment overview. The first is removing or controlling the cause, because a liver that is no longer being injured can stabilize and, in earlier stages, some scarring can soften over years. In practice this means complete abstinence from alcohol where alcohol is the cause; antiviral medicines for hepatitis B or C, which suppress or clear the virus; weight, blood sugar and lipid management in fat-related disease; and immune-suppressing treatment in autoimmune hepatitis. The choice and timing of any medicine sits with the prescribing clinician.
The second pillar is managing complications before they become emergencies. Medicines in the beta-blocker class lower portal pressure to reduce the chance of variceal bleeding, and endoscopic banding can tie off varices directly. Diuretics help the kidneys shed the salt and water behind ascites, alongside dietary sodium restriction. A laxative-type medicine that reduces ammonia absorption from the gut is used to treat and prevent hepatic encephalopathy, the confusion caused by toxins the liver no longer clears. Vaccination against hepatitis A and B and seasonal infections protects a liver with little reserve.
The third pillar is liver transplantation, assessed when function declines past certain thresholds or when a tumor is found within accepted criteria.
Surveillance threads through all three. The blood tests track whether cause control is working and whether complications are approaching. The scan watches for the tumor that, caught small, keeps the full range of options open, including transplant. Seen this way, the six-monthly visit is not separate from treatment; it is the mechanism by which treatment stays matched to the liver’s current state.
What people often get wrong about cirrhosis surveillance
Certain misunderstandings come up so often in clinic that they deserve naming directly.
Feeling well means the scan can wait. Early liver cancer causes no symptoms, so feeling well is the expected state of the person surveillance is designed to help. Skipping a round because nothing is wrong inverts the logic of the program.
A clear scan means the liver is healing. A negative result means no new nodule was seen on that day. It says nothing about whether scarring has improved, and it does not lower future risk.
A normal AFP rules out cancer. Many early tumors never raise AFP. The marker is a supplement to the scan, not a stand-alone test.
A nodule means cancer. Cirrhotic livers are full of nodules, most of them regenerative. The majority of small nodules found on surveillance turn out to be benign on follow-up or contrast imaging.
Ultrasound diagnosed my cirrhosis, so it tells my team everything. Ultrasound suggests cirrhosis; diagnosis usually combines bloods, elastography and sometimes biopsy. And in surveillance its job is entirely different: spotting change, not confirming the baseline.
Once hepatitis C is treated, scans can stop. Clearing the virus removes the injury but not the existing scar. People with cirrhosis before treatment are generally advised to continue surveillance, a decision made with their team.
Stopping drinking removes the risk. Abstinence is one of the most powerful things anyone with alcohol-related cirrhosis can do, and it can stabilize the liver. The cancer risk that comes from the scar itself remains, which is why surveillance continues.
CT or MRI would obviously be better, so ultrasound is second-rate care. Cross-sectional imaging is more sensitive but brings radiation, contrast and incidental findings. Ultrasound is the guideline-recommended default precisely because its trade-offs suit lifelong repetition; alternatives are chosen when it cannot see well.
Questions to ask your care team
A surveillance appointment is short, and the questions that matter can evaporate under the fluorescent light. Writing a few down beforehand makes the visit work harder for you. These are the ones hepatology nurses say people most often wish they had asked.
- What is the cause of my cirrhosis, and is it still actively injuring my liver, or has that been controlled?
- Am I currently compensated or decompensated, and what changes in my blood results would signal a shift?
- How well could my liver be seen on the last ultrasound? Was the visualization score adequate, or should we consider CT or MRI?
- Is AFP part of my program here, and if so, what trend in my results would prompt further imaging?
- Was my spleen size or platelet count mentioned in the report, and do I need an endoscopy to check for varices?
- If a nodule is found, what happens next and how quickly will I hear?
- How will results be communicated to me, and whom do I contact if I have not heard by a certain point?
- Are there vaccinations I should have, given that my liver has less reserve?
- Should I avoid any over-the-counter medicines or supplements, and which ones?
- Would I be a candidate for transplant assessment at some stage, and what would trigger that conversation?
- If I have hepatitis B or C, or had it in the past, does that change how long I stay in surveillance?
- Who is my point of contact between appointments if something changes?
Not every question will have a crisp answer, and some will prompt the team to say that the evidence is uncertain. That is a useful answer too. The goal is a shared understanding of where your liver stands today and what each test is watching for, so that the six-monthly visit feels like a plan rather than a ritual.
When to call your doctor
Surveillance is built around scheduled visits, but cirrhosis does not always keep to the calendar. Some developments need same-day medical attention rather than waiting for the next scan. Contact emergency services or go to an emergency department straight away if you vomit blood or material that looks like coffee grounds, or pass black, tarry or very dark sticky stool; these can mean bleeding from varices and are an emergency in anyone with cirrhosis.
Seek urgent care, the same day, for new or worsening confusion, unusual drowsiness, difficulty concentrating or a change in personality noticed by those around you, since these can signal hepatic encephalopathy. The same applies to a fever combined with abdominal pain or tenderness, especially if you have ascites, because fluid in the abdomen can become infected; to an abdomen that swells rapidly over days or becomes tight and painful; to yellowing of the skin or eyes that is new or clearly deepening; to a marked drop in how much urine you pass; and to bleeding from the gums or nose that will not stop, or bruising appearing without injury.
Call your liver clinic or family doctor within a few days for less acute changes: steady unexplained weight loss, loss of appetite that persists, new dull pain under the right ribs, swelling of the ankles that is getting worse, or itching that disturbs sleep. None of these confirms a problem, and several have ordinary explanations, but in cirrhosis they warrant a check rather than a wait.
Call, too, if you have missed a surveillance appointment or been told a scan was poorly visualized and have not heard about a follow-up. Chasing an overdue scan is not being a nuisance; it is part of how the program works. Whatever the symptom, the assessment and any decision about treatment rest with your treating team, who know your history and your most recent results.
Frequently asked questions
Can cirrhosis be diagnosed via ultrasound?
Ultrasound can strongly suggest cirrhosis but rarely confirms it alone. Signs include a nodular liver surface, coarse texture, a shrunken right lobe, an enlarged spleen and fluid in the abdomen. Early cirrhosis can look nearly normal, so diagnosis usually combines blood tests, transient elastography to measure liver stiffness, and occasionally a biopsy. Your hepatology team weighs all of these together.
What are the different types of liver cirrhosis?
Cirrhosis is grouped by cause, by stage and, less often, by nodule size. Causes include alcohol, hepatitis B and C, fat-related liver disease, autoimmune hepatitis, bile duct diseases and inherited iron or copper overload. By stage, compensated cirrhosis has few symptoms, while decompensated cirrhosis has complications such as jaundice, ascites, bleeding or confusion. The stage shapes day-to-day care most.
Can a cirrhotic liver cause splenomegaly?
Yes. A scarred liver resists blood flow from the portal vein, raising pressure in the vessels behind it. The spleen, upstream in that system, becomes congested and enlarges, a finding called splenomegaly. The enlarged spleen then traps platelets, which is why people with cirrhosis often have a low platelet count. Ultrasound measures the spleen as an indirect gauge of portal pressure.
What is the best treatment for liver cirrhosis?
There is no single best treatment, because scarring cannot be removed directly. Care rests on controlling the cause, such as abstaining from alcohol or treating viral hepatitis; managing complications like varices, ascites and encephalopathy; and assessing for transplant when function declines or a tumor is found. Regular surveillance keeps those decisions matched to the liver’s current state, under the treating team’s guidance.
How often should cirrhosis patients have an ultrasound?
The usual interval is about every six months, which is the schedule the NHS describes for people with cirrhosis being checked for liver cancer. The gap balances the slow growth of small liver tumors against the burden of repeated appointments. Some people are scanned sooner if a tiny nodule needs watching, and the exact plan is set by the hepatology team.
Why are cirrhosis blood tests done alongside the scan?
The scan shows structure; the blood tests show function. Bilirubin, albumin and INR reveal how much work the liver can still do, platelets hint at portal pressure, creatinine and sodium feed into severity scores, and AFP acts as a tumor marker. Read together across visits, these trends tell the team whether the liver is stable or drifting toward decompensation.
Does liver cancer screening in cirrhosis stop after hepatitis C treatment?
Usually not, if cirrhosis was present before treatment. Clearing the virus removes the ongoing injury but does not erase existing scar tissue, and the cancer risk that comes from the scar remains. Most guidelines advise continuing six-monthly surveillance in these circumstances. Whether and when it could ever be paused is a decision for the treating team based on individual risk.
What does it mean if the ultrasound finds a nodule?
It means further assessment, not a diagnosis. Cirrhotic livers contain many regenerative nodules, and most small ones turn out to be benign. Depending on size, the team may repeat the ultrasound sooner or arrange a multiphase CT or MRI with contrast. On those scans, a tumor shows a characteristic pattern of early enhancement and washout that often allows diagnosis without a biopsy.
Do I need to fast before a liver ultrasound?
Most departments ask you not to eat for several hours beforehand, and the appointment letter will give the exact instruction. A full stomach and gas in the bowel sit in front of the liver and block the sound waves, degrading the image. Water is usually allowed. Follow your own department’s guidance, and take regular medicines unless specifically told otherwise by the clinic.
Is a six-monthly ultrasound safe to repeat for years?
Yes. Ultrasound uses sound waves rather than ionizing radiation and needs no contrast injection for standard surveillance, so there is no known cumulative harm from repeating it indefinitely. That safety profile is a main reason guidelines recommend it as the first-line surveillance tool. CT, by contrast, carries radiation that adds up over years, which is one reason it is reserved for specific situations.
References
- NHS: Liver cancer
- NHS: Cirrhosis
- MedlinePlus: Alpha-fetoprotein (AFP) tumor marker test
- CDC: Hepatitis B
This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.
More from the Blog
Is the Virus Really Gone? The Follow-Up Test After Hepatitis C Treatment Explained
The follow-up test after hepatitis C treatment is a blood test for the virus's genetic material (HCV RNA), usually taken about 12 weeks after…
When Abnormal Liver Tests Need a Specialist: Who Refers, Who Waits and Who Is Scanned
Most abnormal liver tests are mild, temporary and managed in primary care with a repeat blood panel after a few weeks. A hepatologist referral…
Why Is the Gallbladder Removed After Gallstone Pancreatitis? Timing and Reasoning
After gallstone pancreatitis, the gallbladder is usually removed because it is the source of the stones that blocked the pancreatic duct, and leaving it…
Living With a PEG Feeding Tube: Showering, Sleeping, Going Out and Staying Active
Most people living with a PEG tube can shower, sleep in their usual position, leave the house and stay physically active once the stoma…
Hepatitis A Myths: Does It Become Chronic and Can You Catch It Twice?
Hepatitis A does not become chronic. The infection is acute: the immune system clears the virus, and the liver typically heals without lasting damage,…
Bleeding Peptic Ulcer: The Warning Signs That Call for Emergency Care, Not a Wait-and-See
A bleeding peptic ulcer is an emergency when it causes vomiting of blood or material that looks like coffee grounds, black or tarry stools,…






